AGIO - アギオス・ファ―マシュ―ティカルズ （Agios Pharmaceuticals Inc.）

Agios Pharmaceuticals done well after its pivot to rare diseases. Click here for more on AGIO stock.

Benzinga Pro data, Agios Pharmaceuticals (NASDAQ: AGIO ) reported Q1 sales of $5.61 million. Earnings fell to a loss of $81.02 million, resulting in a 321.81% decrease from last quarter. In Q4, Agios Pharmaceuticals earned $36.53 million and total sales reached $4.31 million. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com

BOSTON, MA / ACCESSWIRE / May 10, 2023 / The BWB Awards at Biotech Week Boston returns for a night of dinner, drinks, entertainment, and the recognition of the top individuals, companies, and organizations in the life sciences community. Since 2018, the Awards at the Biotech Week Boston festival have been bringing together the faces and names that make the Boston community the beating heart of the biotech world. Join 150+ leaders across the entire life science spectrum at the BWB Awards 2023. About the BWB Awards: Nominations are now open to honor what makes the life sciences ecosystem vibrant and innovative. Submit by May 19 th . Nomination categories include: START-UP OF THE YEAR - The Start-up of the Year award recognizes a burgeoning company that has blossomed into an industry leader through growth and innovation. DE&I INITIATIVE - The DE&I Initiative award recognizes an organization or group that has advanced diversity, equity, and inclusion in the workplace by championing the perspectives and contributions of employees representing marginalized groups.

Agios Pharmaceuticals, Inc. (NASDAQ:NASDAQ:AGIO) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ETCompany ParticipantsCecilia Jones – Chief Financial OfficerBrian Goff – Chief…

The following slide deck was published by Agios Pharmaceuticals, Inc.

The share price of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) fell to $26.06 per share on Thursday from $26.52. While Agios Pharmaceuticals Inc. has underperformed by -1.73%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGIO fell by -9.70%, with highs and lows ranging from $34.76 to $16.75, […]

Agios Pharmaceuticals, Inc. (NASDAQ:NASDAQ:AGIO) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ETCompany ParticipantsJessi Rennekamp - Senior Director, Corporate…

Agios Pharmaceuticals press release (AGIO): FY GAAP EPS of -$4.23 beats by $2.06.Revenue of $14.24M beats by $0.35M.$1.1 Billion of Cash, Cash Equivalents and Marketable Securities…

Agios Pharmaceuticals is looking to expand indications for the label into secondary conditions such as sickle cell disease. See why AGIO stock is a Hold now.

Agios Pharmaceuticals will release its earnings data before the market opens on Thursday, February 23rd. Analysts expect Agios Pharmaceuticals to post earnings of per share for…

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) marked $30.78 per share on Wednesday, up from a previous closing price of $29.75. While Agios Pharmaceuticals Inc. has overperformed by 3.46%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGIO fell by -1.25%, with highs and lows ranging from $34.76 to […]

The following slide deck was published by Agios Pharmaceuticals, Inc.

– Consistent and compelling clinical data across rare hematological diseases support five ongoing pivotal trials in thalassemia, sickle cell disease and pediatric pyruvate kinase (PK) deficiency – – Driving toward two additional PYRUKYND ® indications, with potential FDA approvals in thalassemia in 2025 and sickle cell disease in 2026 – – Strong cash position expected to enable completion of ongoing programs and pipeline expansion to cash-flow positivity – CAMBRIDGE, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced its anticipated 2023 milestones and significant value-driving catalysts through 2026 that support the company''s mission to transform patient outcomes in rare diseases. Agios will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT, and a live webcast will be available at investor.agios.com . "Agios is poised for significant growth with the potential for approvals in two additional PYRUKYND ® indications by 2026, and is well capitalized to advance its robust existing clinical pipeline and expand its portfolio within our core areas of expertise," said Brian Goff, chief executive officer at Agios. "As the pioneering leader in PK activation with more than seven years of clinical experience with PYRUKYND ® , we have generated an impressive body of consistent and compelling data across rare hematological diseases with shared underlying pathophysiology that further builds confidence in our five ongoing pivotal clinical trials in thalassemia, sickle cell disease and pediatric PK deficiency.

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares, rose in value on Friday, 12/30/22, with the stock price up by 2.41% to the previous day’s close as strong demand from buyers drove the stock to $28.08. Actively observing the price movement in the last trading, the stock closed the session at $27.42, falling within a range of $26.88 … Agios Pharmaceuticals Inc. (NASDAQ: AGIO): Is It Stable And Growing? Read More »

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) price on Friday, December 23, fall -5.09% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $27.03. A look at the stock’s price movement, the close in the last trading session was $28.48, moving within a range at $26.80 and $28.42. The beta value … Analysts Predicting A Spike In Agios Pharmaceuticals Inc. (NASDAQ: AGIO)? Read More »